Cannabis Dependence Clinical Trial
Official title:
Long-term Effects of Cannabis Use on Social and Emotional Brain Processes in Dependent Cannabis Users After a 28 Day Abstinence Period
Verified date | February 2017 |
Source | University of Electronic Science and Technology of China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this functional magnetic resonance imaging (fMRI) study is to find out whether and how social and emotional brain function are altered in dependent cannabis users relative to healthy non-using control subjects after a 28 supervised abstinence period. Previous research in cannabis users has predominantly focused on cognitive functions. Moreover, studies have implicated that observed deficits in cannabis users may regenerate after a prolonged abstinence period. Findings might provide important information with respect to relapse vulnerability.
Status | Completed |
Enrollment | 43 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria: - Cannabis dependence according to DSM 4 criteria - 28 days of supervised abstinence Exclusion Criteria: - other DSM 4 diagnosis - neurological disorders |
Country | Name | City | State |
---|---|---|---|
Germany | University of Bonn / Department of Psychiatry | Bonn | NRW |
Lead Sponsor | Collaborator |
---|---|
University of Electronic Science and Technology of China | German Research Foundation, University Hospital, Bonn |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | fMRI neural activation patterns of social-emotional brain processes after 28 day abstinence | Activity patterns in core regions of the emotion processing & addiction-related brain networks (e.g. striatal regions, insular cortex, prefrontal cortex) will be assessed after 28-days of abstinence. Alterations will be determined by comparison with matched non-drug using controls | one timepoint = fMRI assessment after 28 day abstinence period | |
Secondary | Ratings of subjective experience (pleasantness, rewarding value) will be assessed after 28 days of abstinence | Self-reported ratings of pleasantness & rewarding value during soft-pleasant touch. | one timepoint = during fMRI assessment after 28 day abstinence period | |
Secondary | Relapse interview assessed with Timeline-Followback Method | Association between fMRI neural correlates and drug use during follow up period as predictor of relapse | one timepoint = 24 months post-fMRI-session |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01005810 -
A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana
|
Phase 2 | |
Completed |
NCT00114439 -
Lithium Cannabis Withdrawal Study
|
Phase 2 | |
Completed |
NCT00350285 -
The Teen Marijuana Check-Up
|
Phase 2 | |
Completed |
NCT01618656 -
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
|
Phase 2 | |
Completed |
NCT01153490 -
Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine
|
Phase 4 | |
Completed |
NCT02946489 -
Facilitating the Behavioral Treatment of Cannabis Use Disorder
|
Phase 1 | |
Completed |
NCT02088177 -
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01565174 -
The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis
|
N/A | |
Completed |
NCT01697709 -
Quetiapine Pharmacotherapy for Cannabis Dependence
|
Phase 2 | |
Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
Completed |
NCT01603992 -
Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
|
||
Completed |
NCT00167297 -
Atomoxetine for the Treatment of Cannabis Dependence
|
Phase 2 | |
Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
Completed |
NCT01611948 -
Treatment for Cannabis Withdrawal and Dependence
|
Phase 2 | |
Recruiting |
NCT03221231 -
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
|
Phase 4 | |
Not yet recruiting |
NCT03366909 -
Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness
|
N/A | |
Completed |
NCT01639872 -
Clozapine for Cannabis Use in Schizophrenia
|
Phase 4 | |
Not yet recruiting |
NCT06334016 -
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
|
Early Phase 1 | |
Completed |
NCT01793961 -
Effects of Chronic Intake of Cannabis on Contrast Sensitivity
|
N/A | |
Completed |
NCT01834794 -
Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders
|
N/A |